DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if you are tracking what analysts are baking into their models. This move sits ...

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 ...

In 2026, consumer wearables do more. They can flag patterns that may point to real health problems, not just a rough wellness trend.

In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...

Researchers have found in a new study that continuous glucose monitoring (CGM) in the ICU appears to provide reliable glucose ...

People don't buy consumer wearables just to count steps anymore. They want early warnings, useful health signals, and features they can trust.

Diabetes Care Devices Market Insights, Competitive Landscape, and Market Forecast - 2034” report provides the current ...

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.

Tandem Diabetes Care, Inc.’s TNDM impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce ...

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...